Disease Introduction
Cardiac arrhythmias are abnormalities in the rhythm or rate of the heartbeat, commonly including atrial fibrillation, premature beats, bradycardia, and conduction block. In atrial fibrillation, the atria fibrillate erratically, making it easier for blood clots to form in the left atrial appendage; if these clots break off, they can cause a stroke. Slow conduction can cause dizziness, blurred vision, or even syncope. The general principles of treatment are to manage the rhythm, prevent stroke, and, if necessary, use pacing. Treatment options include medication, ablation, occlusion, or pacemakers, depending on the type of arrhythmia.
Cutting-edge high-precision diagnostic and treatment technologies
- Domestic PFA Approved : In 2025, the National Medical Products Administration approved a number of domestic pulsed electric field ablation (PFA) innovative products (Xuanyu, Yingtailiankang, Aikemai, etc.). PFA selectively damages atrial tissue with non-thermal energy without harming the esophagus and phrenic nerve.
- Cryoablation Expansion : The 2025 Medical Device Registration Work Report disclosed that domestically produced cardiac cryoablation equipment and disposable cryoablation probes have been approved, mainly for pulmonary vein isolation in adults with persistent atrial fibrillation.
- Leadless pacing tops the journal : A global study of leadless pacemakers (725 cases from 56 centers in 19 countries) in which Zhang Shu's team from Fuwai Hospital participated was published in the New England Journal of Medicine. Capsule pacemakers do not require chest incisions or leads.
- Upgraded left atrial appendage occlusion : The "Expert Consensus on Clinical Pathways for Transcatheter Left Atrial Appendage Occlusion in China (2025 Edition)" clarifies the applicable population; the 3-year follow-up of the OPTION trial shows that left atrial appendage occlusion performed concurrently with atrial fibrillation ablation is superior to anticoagulation alone in terms of safety endpoints.
- Smart screening guidelines : The Chinese Guidelines for the Management of Atrial Fibrillation (2025) recommend opportunistic screening for people aged 65 and above; implantable ECG monitors have a 1-year atrial fibrillation detection rate that is about 7 times higher than that of traditional monitoring in patients with cryptogenic stroke.
